SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of UX111, a gene therapy for Sanfilippo syndrome type A, is driving attention, with traders highlighting the first approved treatment for the disease and a potential priority-review voucher. The community is broadly bullish but debating the muted share-price reaction, commercialization constraints, cost-cutting needs, and whether short covering or additional company news will be required for further momentum.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves proposed convertible-note financing and ATM share-sale program have driven attention, with traders focused on added leverage, potential dilution, and managements timing as the stock fell despite broader AI strength. Some bulls argue the capital will fund expansion backed by strong compute demand and new higher-priced contracts, but near-term sentiment is dominated by financing concerns.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Ninth Circuit ruling that sports-event contracts are bets rather than federally protected swaps is drawing attention as a potential regulatory win for DraftKings, weakening Kalshi and other prediction-market competitors and strengthening traditional sportsbook protections. Traders remain divided, with bulls citing the ruling and NFL-season demand while skeptics point to possible Supreme Court review, continued competition, and DraftKings own exposure to prediction markets.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

A sharp semiconductor and AI-led rebound, reinforced by bullish options flow and short-squeeze speculation, has driven attention to AMD. Traders remain divided between expectations of continued momentum from strong AI-chip demand and concerns that the move is overextended, richly valued, and vulnerable to a pullback amid further rate hikes.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A sharp, high-volume move without a confirmed company-specific announcement has traders focused on a technical breakout, possible short covering, and speculation around upcoming Anktiva catalysts such as papillary bladder-cancer review and lymphopenia data. Debate remains whether the rally reflects institutional or broader biotech buying and Nant/PDSB developments, or a recurring momentum-driven move vulnerable to a pullback.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generac is drawing attention after signing a long-term agreement to supply Amazon with backup generators for data centers, reinforcing its positioning as an AI-infrastructure power supplier. Traders are broadly bullish on the added revenue visibility and potential for further hyperscaler orders, while others are focused on profit-taking, warrant-related dilution, and the fact that the deals maximum value is not fully committed.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Exploratory reports that SK Hynix may use Intels planned Ohio facility for U.S. memory production, potentially through a lease or joint venture, are driving attention and bullish positioning. Traders view the talks as a foundry and AI-memory catalyst, while skeptics note that SK Hynix has said no agreement has been finalized and warn the move could fade.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

A well-received investor presentation and optimism around Schrodingers AI-powered drug-discovery platform and growing Big Pharma interest are driving the sharp move. Traders are split between viewing it as a durable re-rating and warning that the stock is overbought, with some speculating about future partnerships or a buyout without confirmation.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeonas slower-than-expected ZEVASKYN commercial ramp and manufacturing issue that left one treatment non-billable are driving attention after the latest quarterly update, alongside continued concern about treatment-center activation, cash burn, and management guidance. Traders remain divided: bears question demand, execution, and dilution risk, while bulls view the setback as temporary and focus on expanding treatment centers and potential upside from partner Ultragenyxs UX111 FDA decision.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

A post-earnings selloff is driving attention after T-Mobile delivered stronger profit but slightly missed revenue expectations and signaled slower account growth, prompting debate over whether the decline is an overreaction. Bulls view the shares as oversold and a buying opportunity, while bears cite valuation, debt, intensifying wireless competition and the potential threat from Starlink.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A10 Networks Appoints Mary C. Henry to the Board of Directors

A10 Networks (NYSE: ATEN) today announced it is appointing Mary C. Henry to the Board of Directors, effective October 5, 2026. Henry spent 18 years at Goldman Sachs, primarily as a communications technology analyst in the firms Investment Research division. She joins current directors, Tor R...

Intercontinental Exchange Adds to Weather Tracking Features: NYSE Content Update

Intercontinental Exchange Adds to Weather Tracking Features: NYSE Content Update Intercontinental Exchange Adds to Weather Tracking Features: NYSE Content Update PR Newswire NEW YORK, Sept. 1, 2026 NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, Sept. 1, 2026...

A10 Networks Launches A10 AI Gateway, an Intelligent Control Plane for All AI Operations

A10 Networks (NYSE: ATEN) today announced the general availability of the A10 AI Gateway, a centralized, intelligent control plane that gives organizations unified routing, cost management, and governance across every AI agent, application and large language model (LLM) they use. The company...

A10 Networks (ATEN) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

A10 Networks (ATEN) Q2 Earnings Miss Estimates

A10 Networks (ATEN) delivered earnings and revenue surprises of -3.85% and +3.72%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

A10 Networks Reports Financial Results for the Second Quarter of 2026

A10 Networks, Inc. (NYSE: ATEN), a leading provider of secure application services and solutions, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Financial Summary Quarterly revenue of $80.1 million, a 15.5% year-over-year increase. Revenue for the...

Palantir Technologies Inc. (PLTR) Q2 Earnings and Revenues Top Estimates

Palantir Technologies (PLTR) delivered earnings and revenue surprises of +17.14% and +7.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

A10 Networks to Announce Second Quarter 2026 Financial Results on August 5, 2026

A10 Networks (NYSE: ATEN) today announced that the companys second quarter 2026 financial results will be released after the markets close on Wednesday, August 5, 2026. Management will host a call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results.Interested parties...

5 Small and Mid-Cap AI Stocks to Buy That Have Skyrocketed in 1H 2026

BAND, AIP, PENG, ATEN and VECO are among small- and mid-cap AI stocks that surged in 1H 2026 with more room to grow in 2H.


Is Applied Materials (AMAT) Outperforming Other Computer and Technology Stocks This Year?

Here is how Applied Materials (AMAT) and A10 Networks (ATEN) have performed compared to their sector so far this year.

A10 Networks, Inc. engages in the provision of networking solutions. It offers security, hybrid cloud, service providers, vertical solutions, and mobile carriers. It operates through the following geographical segments: Americas, Asia-Pacific and Japan (APJ), and Europe, the Middle East, and Africa (EMEA). The Americas segment includes all other countries in the Americas, excluding the Unites States. The APJ segment is involved in all countries in the Asia Pacific region including Japan. The company was founded by Lee Chen in 2004 and is headquartered in San Jose, CA.

A10 Networks Inc

Bullish Sentiment

$CRWD

$PANW

$NET

Cybersecurity is one of the market's most crowded trades right now, and $CRWD, $PANW, $NET, and $ZS each represent a different bet on where the next leg of growth comes from. If you had to put your money behind just one for the next 12 months, which are you choosing? Explain your reasoning in the comments.

Which cybersecurity stock will post the best performance over the next 12 months? 
 
Drop a comment for other tickers.

Stocktwits

Stocktwits Polls

$ATEN IMO, not a buy signal, but if the 5-day EMA (green line) crosses above both those moving averages it is hovering below, a buy signal could materialize., maybe around the 27.50 mark

John (aka Dojidad)

🚨 $ATEN WATCH 🚨

A10 Networks is showing some serious strength today, up nearly 4% and pushing back toward the $26 area. 📈

The important part now is CONFIRMATION.

👀 Holding $26 = bullish momentum remains intact
🔥 Break above the recent highs + strong volume = potential continuation
⚠️ Losing $25.50–$25 = momentum starts weakening

Fundamentally, A10 just delivered a strong Q2 with 15.5% YoY revenue growth and an EPS beat. 💰

I’m watching $ATEN closely here — don’t chase the candle. Watch the levels and let price confirm the move. 🎯📊

Feed

News

Sentiment

Earnings

Fundamentals

Info

ATEN A10 Networks Inc

Fundamentals

Latest ATEN News